Treatment of Intestinal and Hepatic Mucormycosis in an Immunocompromized Child

被引：20

作者：

Lueer, Sonja ^{[1
]}

Berger, Steffen ^{[2
]}

Diepold, Miriam ^{[1
]}

Duppenthaler, Andrea ^{[3
]}

von Gunten, Michael ^{[4
]}

Muehlethaler, Konrad ^{[3
]}

Wolf, Rainer

Aebi, Christoph ^{[3
]}

机构：

[1] Univ Bern, Dept Pediat, Div Pediat Hematol Oncol, CH-3010 Bern, Switzerland

[2] Univ Bern, Dept Pediat Surg, CH-3010 Bern, Switzerland

[3] Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland

[4] Univ Bern, Inst Pathol, CH-3010 Bern, Switzerland

来源：

PEDIATRIC BLOOD & CANCER | 2009年 / 52卷 / 07期

关键词：

Absidia corymbifera; child; intestinal; liver; mucormycosis; posaconazole; zygomycosis; GASTROINTESTINAL MUCORMYCOSIS;

D O I：

10.1002/pbc.21918

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

During ALL chemotherapy, a 4-year-old patient presented with febrile neutropenia and abdominal pain. Ultrasound examinations were repeatedly normal. Computerized tomography on clay 7 demonstrated appendicitis and multiple hepatic foci identified as mucormycosis (Absidia corymbifera). Successful outcome was achieved by aggressive re-surgery, long-term antifungal therapy with serum level-monitored posaconazole, and recovery of neutrophil counts. Considering the interference of posaconazole with CYP3A4, vincristine was administered during 72 hr posaconazole windows. Pediatric intestinal mucormycosis, still associated with a >70% case-fatality rate, calls for early imaging and Surgery to establish the diagnosis, reduce the fungal mass, and provide a rationale for using posaconazole. Pediatr Blood Cancer 2009;52:872-874. (C) 2009 Wiley-Liss, Inc.

引用

页码：872 / 874

页数：3

共 20 条

[1]

Agarwal Kiran, 2006, Indian J Pathol Microbiol, V49, P430

[2]

AlAsiri RH, 1996, AM J GASTROENTEROL, V91, P606

[3]

Neonatal colonic mucormycosis - A tropical perspective [J].